Table 2. Summary of cohort characteristics.
| Breed | Sex | Age (year) | Body weight (kg) | Diagnosis | Hx-Surgery | Hx-RT | Hx-chemotherapy* | TNM classification | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cairn Terrier | MI | 10 | 6.1 | Tonsil SCC | 4 months ago, 28 Gy/4 fract | Low CBDCA (2) metronomic chemotherapy | T3bN3M0 | |
| 2 | Labrador Retriever | MI | 15 | 27 | Intranasal TCC | AO-PDT(37 months ago) | 36 months ago, 28 Gy/4 fract | Low CBDCA (5) | T3N0M0 |
| 3 | Dachshund | MI | 11 | 7.3 | ASAGACA | Obstruction of enlarged sub-lumber LN 2 months ago | Low CBDCA (3) | T0N0M1 | |
| 4 | Cocker Spaniel | FS | 11 | 9.8 | ASAGACA | 14 months ago | Low CBDCA (14) | T2N1bM0 | |
| 5 | Boston Terrier | FI | 10 | 8.5 | Malignant mixed tumor of mammary gland | 12 months ago | Low CBDCA (5) | T3N1M1 | |
| 6 | Dachshund | MC | 14 | 4.5 | OMM | 5 months ago | 4 months ago, 22 Gy/4 fract | Low CBDCA (4) | T3bN1bM1 |
| 7 | Mixed breed | FS | 16 | 9.6 | IMC | 1 month ago | T4N1M1 | ||
| 8 | Cocker Spaniel | MI | 10 | 14 | ASAGACA | 9 months ago | Low CBDCA (10) | T0N1M0 | |
| 9 | West Highland White Terrier | MC | 9 | 8.3 | Intranasal AC | AO-PDT (23 months ago) | 22 months ago, 43 Gy/15 fract | Low CBDCA (12) | T3N1M0 |
| 10 | Mix | MC | 12 | 20.7 | Intranasal TCC | AO-PDT(3 months ago) | 4 months ago, 44 Gy/11 fract | Toceranib | T1N0M0 |
| 11 | Toy Poodle | MI | 12 | 5.0 | Intranasal AC | 3 years ago, 30 Gy/4 fract, Re-RT (4 months ago, 15 Gy/2 fract), re-RT (1 month ago,12 Gy/2 fract) | Toceranib, and low CBDCA (3) | T3N0M0 | |
*The number in parentheses shows the number of CBDCA administrations. AC: adenocarcinoma, AO-PDT: acridine orange photodynamic therapy and cribriform irradiation, ASAGACA: anal sac apocrine grand adenocarcinoma, FI: female intact, FS: female spayed, Hx: history, IMC: inflammatory mammary carcinoma, LN: lymph node, MC: male castrated, MI: male intact, OMM: oral malignant melanoma, RT: radiotherapy, SCC: squamous cell carcinoma, Sx: surgery, TCC: transitional cell carcinoma, low CBDCA: low-dose carboplatin, 100–120 mg/m2 (treatment number).